Why Iovance Biotherapeutics Has Caught Investor Attention

Iovance Biotherapeutics (IOVA) has drawn fresh interest after recent trading sessions, as investors weigh its commercial stage cell therapy profile alongside sharp moves in the share price over the past month.

The stock shows a 103% return over the past month and 128% over the past 3 months, placing recent momentum against a backdrop that includes revenue of US$263.502 million and a net loss of US$390.978 million.

The recent 12.01% 1 day share price return and strong short term gains, including a 35.36% 7 day and 102.77% 30 day share price return, contrast with a 5 year total shareholder return decline of 85.31%, suggesting renewed momentum after a difficult longer term stretch.

If Iovance’s move has you looking across the sector, you may want to scan our screener of 32 healthcare AI stocks to see what else fits your watchlist.

With Iovance posting US$263.502 million in revenue alongside a US$390.978 million loss, yet trading at a large discount to analyst targets and intrinsic estimates, is this genuine mispricing, or is the market already factoring in expectations for future growth?

Most Popular Narrative: 38.6% Undervalued

With Iovance Biotherapeutics closing at $5.13 against a most followed narrative fair value of $8.35, the valuation gap rests on some punchy growth assumptions.

The ongoing streamlining of operations and manufacturing, including a 19% workforce reduction and improved capacity utilization at the Iovance Cell Therapy Center, is set to significantly reduce cost of sales and improve gross margins, supporting better net margins and long-term profitability.

Want to see what turns a loss of hundreds of millions into projected profitability? The narrative leans on sharp revenue expansion and a step change in margins. Curious which future earnings profile supports that $8.35 number and the discount rate behind it? The full story lays out the math.

Result: Fair Value of $8.35 (UNDERVALUED)

However, this hinges on smooth EMA discussions and sustained demand for Amtagvi, and setbacks on either front could quickly weaken the undervalued narrative.

Another Angle: Pricing Looks Demanding On Sales

That 38.6% “undervalued” fair value is based on future cash flows, but today the market is paying a P/S of 8x for Iovance. That is cheaper than the US Biotechs industry at 12x and peers at 10.4x, yet still above a fair ratio of 4.5x, which hints at meaningful valuation risk if expectations ease.

Next Steps

With sentiment clearly mixed, this may be a good time to look at the underlying numbers yourself and decide how comfortable you are with the trade off between risk and potential reward, starting with 2 key rewards and 3 important warning signs.

Looking for more investment ideas?

If you stop with Iovance, you might miss other opportunities that fit your style, so use the screener to line up your next few research candidates.

• Target potential mispricings by checking companies that currently screen as 50 high quality undervalued stocks, and build a watchlist of ideas to research before the crowd catches on.
• Prioritise resilience by reviewing 66 resilient stocks with low risk scores, giving yourself a starting set of businesses to examine if you want to focus on steadier profiles.
• Get ahead of the market by scouting screener containing 24 high quality undiscovered gems that could add differentiated exposure instead of just sticking with the usual tickers everyone follows.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.